Anti-Obesity Drugs Market by Segments (Contrave, Xenical, Belviq, etc.), 2016 – 2022
Global anti-obesity drugs market segmented by approved drugs: buproprion and naltrexone (Contrave), orlistat (Xenical), lorcaserin (Belviq), phentermine and topiramate (Qsymia), and liraglutide (Saxenda).
Global anti-obesity drugs market segmented by approved drugs: buproprion and naltrexone (Contrave), orlistat (Xenical), lorcaserin (Belviq), phentermine and topiramate (Qsymia), and liraglutide (Saxenda).
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
<strong>Anti</strong>-<strong>Obesity</strong> <strong>Drugs</strong> <strong>Market</strong> <strong>by</strong> <strong>Segments</strong><br />
(<strong>Contrave</strong>, <strong>Xenical</strong>, <strong>Belviq</strong>, <strong>etc</strong>.), <strong>2016</strong> <strong>–</strong> <strong>2022</strong>
P e r s i s t e n c e M a r k e t R e s e a r c h<br />
About Us<br />
Persistence <strong>Market</strong> Research (PMR) is a market intelligence company, providing global business information<br />
reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forwardlooking<br />
insight for thousands of decision makers. We have an experienced team of Analysts, Researchers,<br />
and Consultants, who use proprietary data sources and various tools and techniques to gather, and analyze<br />
information. Our business offerings represent the latest and the most reliable information indispensable for<br />
businesses to sustain a competitive edge.<br />
Each PMR Syndicated Research report covers a different sector - such as pharmaceuticals, chemical,<br />
energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports<br />
provide in-depth analysis and deep segmentation to possible micro levels. With a wider scope and stratified<br />
research methodology, our syndicated reports strive to serve clients and satisfy their overall research<br />
requirement.<br />
Copyright © 2015 Persistence <strong>Market</strong> Research<br />
All Rights Reserved. This document contains highly confidential information and is the sole property of PMR.<br />
No part of it may be circulated, copied, quoted, or otherwise reproduced without the approval of PMR.<br />
<strong>Anti</strong>-<strong>Obesity</strong> <strong>Drugs</strong> <strong>Market</strong>, <strong>2016</strong> - <strong>2022</strong> Page |
P e r s i s t e n c e M a r k e t R e s e a r c h<br />
Report Media Releases<br />
<strong>Anti</strong>-<strong>Obesity</strong> <strong>Drugs</strong> <strong>Market</strong> <strong>by</strong> <strong>Segments</strong> (<strong>Contrave</strong>, <strong>Xenical</strong>, <strong>Belviq</strong>,<br />
<strong>etc</strong>.), <strong>2016</strong> <strong>–</strong> <strong>2022</strong><br />
According to World Health Organization (WHO), obesity refers a disorder of accumulation of excessive fat that can<br />
impair health. Body Mass Index (BMI) is an index of weight for height, which is a measure for classifying obesity and<br />
overweight. According to WHO, BMI greater than or equal to 30 is consider as an Obese. <strong>Anti</strong>-obesity drugs refers the<br />
drugs that reduces or control the body weight <strong>by</strong> either reducing the appetite or increasing the absorption of calories.<br />
The fundamental treatment for obesity is to control over unhealthy diet, and regular exercise, as although anti-obesity<br />
drugs are available in the market, their usefulness is restricted to maintain weight rather than cure. <strong>Obesity</strong> is a risk<br />
factor for development of several chronic diseases such as coronary heart diseases, hypertension, metabolic disorders<br />
such as diabetes, and others. Hence, need to control <strong>by</strong> proper medication, diet, and exercise. Bariatric surgery is an<br />
also option for weight loss for BMI more than 40. However, lifelong changes in eating and exercise habits are necessary<br />
after surgery.<br />
Request to view TOC : http://www.persistencemarketresearch.com/toc/8884<br />
Global anti-obesity drugs market segmented <strong>by</strong> approved drugs: buproprion and naltrexone (<strong>Contrave</strong>), orlistat<br />
(<strong>Xenical</strong>), lorcaserin (<strong>Belviq</strong>), phentermine and topiramate (Qsymia), and liraglutide (Saxenda). Geographically, global<br />
anti-obesity drugs market segmented into North America, Europe, Asia Pacific, Latin America, and rest of the World.<br />
Presently, North America holds largest share of the market due to increasing obese population. For instance,<br />
according to Centers for Disease Control and Prevention (CDC), more than one third of U.S. population is obese in<br />
2014. However, Asia Pacific expected to grow at highest rate due to increasing demand of drugs, and awareness<br />
regarding risk associated with obesity. Additionally, sedentary lifestyle, and unhealthy diet would expect to increase<br />
the number of obese people during forecast period.<br />
Increase in incidence of obesity is majorly due to lack of physical activity, lack of sleep, and high calorie diet. Additionally,<br />
family history, and consumption of certain medicines such as antidepressant, diabetes agent also play a major role in<br />
obesity. For instance, according to World Health Organization (WHO), about 13% of world’s population were obese in<br />
2014. Additionally, according to WHO, in emerging countries the rate of increase of childhood obesity has been more<br />
than 30% higher than that of developed countries. However, several side effects such as risk of psychiatric disorder,<br />
non-fatal myocardial infraction, or stroke could affect the market negatively albeit. Hence, development of medicines<br />
with lesser side effects with chronic use, and increasing focus on developing countries market can help to boost the<br />
market.<br />
Recently, in September 2014 U.S. FDA approved <strong>Contrave</strong>, an extended release tablet for chronic weight management.<br />
<strong>Contrave</strong> is a combination of two already FDA-approved drugs, naltrexone and bupropion, and distributed <strong>by</strong> Takeda<br />
Pharmaceuticals America Inc. However, the drug is acting <strong>by</strong> very different mechanism of mesolimbic pathway. Hence,<br />
approval of such a drugs in the market could expect to surge the market growth.<br />
Request to view Sample Report : http://www.persistencemarketresearch.com/samples/8884<br />
Key players in the global anti-obesity market are Arena Pharmaceuticals, Bristol-Myers Squibb, Alizyme, Boehringer<br />
Ingelheim GmbH, Eisai Company, Ltd., F. Hoffmann-La Roche, GlaxoSmithKline plc, Bayer AG, Inc., Novo Nordisk,<br />
<strong>Anti</strong>-<strong>Obesity</strong> <strong>Drugs</strong> <strong>Market</strong>, <strong>2016</strong> - <strong>2022</strong> Page |
P e r s i s t e n c e M a r k e t R e s e a r c h<br />
and Norgine Pharmaceuticals Ltd. Additionally, some other company includes Orexigen Therapeutics, Pfizer, Inc.,<br />
Takeda Pharmaceutical, Rhythm Pharmaceuticals, Shionogi USA, Vivus, Inc., and Zafgen.<br />
For information regarding permissions, contact:<br />
Persistence <strong>Market</strong> Research<br />
90 Sate Street, Suite 700 Albany, NY 12207<br />
Tel: +1-518-618-1030<br />
Email: sales@persistencemarketresearch.com<br />
Website: http://www.persistencemarketresearch.com/<br />
media@persistencemarketresearch.com<br />
<strong>Anti</strong>-<strong>Obesity</strong> <strong>Drugs</strong> <strong>Market</strong>, <strong>2016</strong> - <strong>2022</strong> Page |